top of page

Lab testing news for telehealth and fertility programs: week of Nov 9, 2026

5 days ago
4 min read
Flat illustration on a navy background of a PrEP calendar with checked dates, a laptop telehealth visit, a fertility results chart and a rack of specimen tubes linked by a pink dotted path

This week's lab-testing roundup covers four stories for telehealth, PrEP and fertility programs: new PURPOSE 5 data on staying on injectable PrEP, Maven Clinic's move in-network for hormone care, a large IVF study on AMH and antral follicle count discordance, and the shift of CDC HIV prevention money from community groups to health departments.



Twice-yearly lenacapavir nearly doubles one-year PrEP persistence in PURPOSE 5


On Nov 6, 2026, Gilead reported results from PURPOSE 5, a Phase 2 randomized study in the UK and France being presented at HIV Glasgow 2026. Among 267 participants who were not taking PrEP at enrollment, 85.6% of those starting twice-yearly injectable lenacapavir stayed persistent through Week 52, compared with 46.3% of those starting daily oral F/TDF. Gilead reported zero HIV acquisitions in the lenacapavir arm during the study period. The trial was run outside the US, so it is evidence about engagement, not a US regulatory change.


What it means for B2B programs: if more patients stay on long-acting PrEP, the lab schedule becomes the backbone of the program. The US prescribing information for Yeztugo, summarized in the same release, requires HIV-1 testing before starting and before each injection, using an FDA-approved or cleared test for acute or primary HIV-1 infection. That makes test timing, specimen collection and results turnaround a scheduling problem tied to each injection visit, not an afterthought. Programs typically also layer in STI screening at the cadence their clinicians set. Teams mapping this out can compare their workflow with our PrEP and STI lab testing overview and our earlier oral vs. injectable PrEP lab-monitoring checklist.



Maven Clinic brings virtual hormone care in-network


On Nov 11, 2026, Maven Clinic announced that care through its virtual clinic is now in-network with more than 475 health plans, which the company says represents around 80% of commercially insured lives. Perimenopause, menopause and hormone care visits are available now, with OB-GYNs, maternal-fetal medicine specialists, nurse practitioners and nutritionists to follow in the coming months. Starting January 2027, employers can promote the in-network clinic to employees for needs such as PCOS, endometriosis, and hormonal, sexual and metabolic health.


What it means for B2B programs: insurance-billed virtual visits change what a lab workflow has to support. Hormone and midlife care often involves bloodwork, and patients seen virtually may live far from the clinician. Women's health and hormone platforms planning for in-network care tend to revisit a few questions: which panels are ordered at baseline and at follow-up, how specimens get collected when the patient is remote, how results route back to the treating clinician, and how billing and coverage rules apply to the lab portion of care, not only the visit. A telehealth lab partner model is one way platforms split those responsibilities between the care team and the laboratory.



AMH and antral follicle count discordance linked to lower first-cycle IVF yields


A retrospective study published Nov 4, 2026 in the Journal of Assisted Reproduction and Genetics (DOI link), summarized by IVF.net on Nov 6, looked at 6,456 patients in their first IVF or ICSI cycle at a center in Ningbo, China. About 12.6% had discordant ovarian reserve markers, meaning one of AMH or antral follicle count (AFC) was normal and the other was reduced. Compared with patients whose markers were both normal, discordant patients had fewer oocytes, mature oocytes and embryos. Pregnancy outcomes after the first transfer did not differ significantly between the two groups. Within the discordant group, normal AMH with low AFC was linked to higher yields than the reverse pattern.


What it means for B2B programs: the study, which shows associations rather than causes, is a reminder that AMH is one input to ovarian reserve assessment, not a stand-alone answer. For fertility clinics and fertility benefit programs, that argues for workflows that keep AMH results easy to pair with ultrasound findings, consistent reference ranges across sites, and clear documentation of which marker is reduced. Programs offering remote AMH collection should make sure results land somewhere the clinician sees them alongside the rest of the workup. For more on how labs support this testing, see our AMH testing page.



CDC HIV prevention funding moves from community groups to health departments


Two reports this week showed how the end of direct CDC funding for community-based organizations (CBOs) is playing out locally. North Carolina Health News reported on Nov 10 that the CDC did not renew a five-year grant that had funded HIV prevention through 96 CBOs nationally. Charlotte's PowerHouse 2.0 closed at the end of September. North Carolina received $1,785,603 in supplemental health-department funding and says 30% is supporting community groups, partly through the state public health lab supplying HIV/STI testing support and rapid test kits. On Nov 12, the Texas Tribune reported that Texas lost $29.2 million under the same program (PS21-2102), which had funded 11 community organizations in the state.


What it means for B2B programs: testing dollars are moving toward state and local health departments, and community programs are looking for ways to keep testing going with less money. For organizations planning outreach testing, that raises practical questions about mail-out kits for STI screening, how HIV testing fits with the assay and collection method a clinician requires, and how results and linkage to care are handled when a program has fewer staff. Our guide to setting up an employer STI testing program covers many of the same logistics, from test menus to private results.



What this week's stories share


The common thread is that lab testing follows the patient. Long-acting PrEP ties HIV testing to every injection visit. In-network virtual hormone care brings bloodwork to people seen from home. Ovarian reserve research shows why fertility results need context. Shifting public-health funding pushes community testing to find leaner workflows. In each case, the clinical decision stays with the ordering clinician, while the program has to get collection, testing and results routing right.


This roundup is educational industry news, not medical advice. IHDLab is a CLIA-certified laboratory (05D2040304) licensed in California, New York and Maryland that works with B2B telehealth, fertility and digital health programs.

bottom of page